Copertina

Contribution of QRS Prolongation to Transplant‐Free Survival in Sarcoidosis‐Related Pulmonary Hypertension

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Juan V. Rodriguez, Haihua Zhang, Nathan Mesfin, Elizabeth S. Klings, Justin K. Lui
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Pulmonary Circulation
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Revised Precapillary Pulmonary Hypertension Criteria and Their Prognostic Value in IPF Transplant Waitlist Survival
di: Zehra Dhanani, et al.
Pubblicazione: (2025)

Risk Assessment Models and Event‐Free Survival in Pulmonary Arterial Hypertension
di: Clara Hjalmarsson, et al.
Pubblicazione: (2025)

Pulmonary Vascular Compromise Is Associated With Survival in Pediatric Pulmonary Hypertension: A New Computational Model
di: Maria Niccum, et al.
Pubblicazione: (2025)

Lung Transplant Outcomes in Patients With Preoperative Catheterization Indicating Group 2 Pulmonary Hypertension
di: Víctor M. Mora‐Cuesta, et al.
Pubblicazione: (2025)

Association of Antidiabetic Medication Classes With Survival Outcomes in Pulmonary Hypertension Patients With Diabetes
di: Aaron W. Trammell, et al.
Pubblicazione: (2026)

Identification of RUNX1 as a Biomarker for Right Ventricular Remodeling in Pulmonary Arterial Hypertension Using WGCNA
di: Wenjie Chen, et al.
Pubblicazione: (2026)

Exploring Health‐Related Quality of Life in Children With Pulmonary Hypertension
di: Jo Wray, et al.
Pubblicazione: (2025)

Prevalence and Economic Burden of Pulmonary Hypertension and Pulmonary Arterial Hypertension Among the Medicaid Population
di: Marshaleen Henriques King, et al.
Pubblicazione: (2025)

The Pulmonary Hypertension Global Patient Survey: Understanding the Invisible Burden of Paediatric Pulmonary Hypertension
di: Sadia Quyam, et al.
Pubblicazione: (2026)

My Introduction to Pulmonary Hypertension
di: Harrison W. Farber
Pubblicazione: (2025)

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories
di: Amrit K. Deol, et al.
Pubblicazione: (2025)

Reply To: “Pulmonary Artery Dilatation in Different Causes of Pulmonary Hypertension”
di: Caputo Annalisa, et al.
Pubblicazione: (2025)

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension
di: Werner Seeger
Pubblicazione: (2025)

Pulmonary Hypertension: A Personal Journey
di: Lewis J. Rubin
Pubblicazione: (2025)

Industry Payments and Prescribing Patterns of Pulmonary Hypertension Therapies in the United States
di: Elizabeth S. Tarras, et al.
Pubblicazione: (2026)

Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children
di: Kaushik Parvathaneni, et al.
Pubblicazione: (2026)

American Lung Association Pulmonary Hypertension Roundtable: Executive Summary
di: Nicholas Andreas Kolaitis, et al.
Pubblicazione: (2025)

Prognostic Role of Platelets in Pulmonary Arterial Hypertension
di: Caio Julio Cesar dos Santos Fernandes, et al.
Pubblicazione: (2025)

Heart Rate Variability in Pulmonary Arterial Hypertension
di: Bishal Gyawali, et al.
Pubblicazione: (2025)

The Role of Ion Channels in Pulmonary Hypertension: A Review
di: Han‐Fei Li, et al.
Pubblicazione: (2025)

Towards a Safe Pathway to Biological Parenthood for Pulmonary Arterial Hypertension
di: Jamie D. Ingram, et al.
Pubblicazione: (2026)

Repair of Sinus Venosus Atrial Septal Defect in 2 Patients With Severe Pulmonary Arterial Hypertension
di: Ryo Sakuma, et al.
Pubblicazione: (2026)

Beyond Resistance: Pulmonary Vascular Compromise as a Mechanistic Window Into Pediatric Pulmonary Hypertension
di: Megan Griffiths
Pubblicazione: (2025)

Hank the Heart and Animation‐Based Education for Pulmonary Hypertension
di: Michelle Cash, et al.
Pubblicazione: (2025)

Northern Pulmonary Hypertension: Personal Experience and Brief History
di: Andrey L. Chernyaev
Pubblicazione: (2025)

Reassessment of the Current Iron Deficiency Definition in Pulmonary Hypertension
di: Aurelia E. Reiser, et al.
Pubblicazione: (2025)

How Is Pulmonary Hypertension Characterised and Treated in Children With Trisomy 21? Observations From the TOPP Registry (Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension)
di: Tilman Humpl, et al.
Pubblicazione: (2025)

Developing Benchmarks in the Diagnosis and Treatment of Pulmonary Arterial Hypertension in a Tertiary, Academic Medical Center
di: Cyrus A. Kholdani, et al.
Pubblicazione: (2025)

Pulmonary Arterial Wedge Oxygen Saturation: Does It Confirm Wedge Position in Patients With Pulmonary Hypertension?
di: Ambalavanan Arunachalam, et al.
Pubblicazione: (2025)

Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: A Comparative Study of Biomarkers and Clinical Indicators
di: Yingjun Huang, et al.
Pubblicazione: (2026)

R213G‐Mediated Redistribution of EC‐SOD Protects Against Sugen‐Hypoxia Pulmonary Hypertension in Mice
di: Daniel Colon Hidalgo, et al.
Pubblicazione: (2026)

Balancing Risk and Hope: Insights Into Pregnancy Outcomes in Pulmonary Arterial Hypertension
di: Teresa Segura de la Cal, et al.
Pubblicazione: (2026)

Early Development of Sildenafil for Pulmonary Hypertension: A Retrospective Account
di: Ghazwan Butrous
Pubblicazione: (2025)

Digital Inclusion in a Scottish National Pulmonary Hypertension Population
di: Jamie Ingram, et al.
Pubblicazione: (2025)

Enhancing Drug Development for Paediatric Pulmonary Hypertension—An Integrative Perspective
di: Steven H. Abman, et al.
Pubblicazione: (2025)

Melatonin in Pulmonary Arterial Hypertension: A Promising Adjunctive Therapy
di: Shaher Yar, et al.
Pubblicazione: (2025)

Pulmonary Hypertension Associated With COVID‐19 Interstitial Lung Disease
di: Shreeya Mehta, et al.
Pubblicazione: (2026)

The Pulmonary Hypertension Global Patient Survey: Groups 2 and 3
di: Katherine Bunclark, et al.
Pubblicazione: (2026)

Supplemental Oxygen Decreases Cardiac Effort in Pulmonary Arterial Hypertension
di: Kyle Norton, et al.
Pubblicazione: (2026)

Pulmonary hypertension in the setting of interstitial lung disease: Approach to management and treatment. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative—Group 3 Pulmonary Hypertension
di: Oksana A. Shlobin, et al.
Pubblicazione: (2024)